Dr. Galsky on the HCRN GU14-182 Study Results in Urothelial Cancer

Matthew D. Galsky, MD
Published: Tuesday, Aug 06, 2019



Matthew Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab (Keytruda) versus placebo in patients with metastatic urothelial cancer.

Response rate was a secondary endpoint of the study. In a maintenance study, patients can enter the study having had a complete response (CR) to first-line chemotherapy, Galsky explains. There are differing opinions regarding whether those patients should receive a switch maintenance treatment approach. One side of the argument is that a switch maintenance approach could lead to a real durable complete response in this group of patients, according to Galsky.

However, if chemotherapy has done a really good job, the other argument is those patients should be offered a treatment-free interval. The numbers will be small, but ultimately, physicians will be able to look at the subset of patients who had a CR going into the study and were randomized to pembrolizumab versus placebo, says Galsky. Although, researchers need to be aware because patients who are in a CR when entering the study need to be taken out of the objective response analysis; this is because there's nothing to measure in terms of the response assessment, Galsky explains.
SELECTED
LANGUAGE


Matthew Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab (Keytruda) versus placebo in patients with metastatic urothelial cancer.

Response rate was a secondary endpoint of the study. In a maintenance study, patients can enter the study having had a complete response (CR) to first-line chemotherapy, Galsky explains. There are differing opinions regarding whether those patients should receive a switch maintenance treatment approach. One side of the argument is that a switch maintenance approach could lead to a real durable complete response in this group of patients, according to Galsky.

However, if chemotherapy has done a really good job, the other argument is those patients should be offered a treatment-free interval. The numbers will be small, but ultimately, physicians will be able to look at the subset of patients who had a CR going into the study and were randomized to pembrolizumab versus placebo, says Galsky. Although, researchers need to be aware because patients who are in a CR when entering the study need to be taken out of the objective response analysis; this is because there's nothing to measure in terms of the response assessment, Galsky explains.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x